OsimertinibDrug resistance secondary to C797S mutation and pneumonitis : 2 case reports

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1740卷 / 1期
关键词：
D O I：
10.1007/s40278-019-58148-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：255 / 255
相关论文
共 50 条
  • [31] EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
    Kobayashi, Yoshihisa
    Fujino, Toshio
    Nishino, Masaya
    Koga, Takamasa
    Chiba, Masato
    Sesumi, Yuichi
    Ohara, Shuta
    Shimoji, Masaki
    Tomizawa, Kenji
    Takemoto, Toshiki
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : 727 - 731
  • [32] The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation
    He, Jie
    Zhou, Zhihui
    Sun, Xin
    Yang, Zunhua
    Zheng, Pengwu
    Xu, Shan
    Zhu, Wufu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 210
  • [33] Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future
    Zhang, Die
    Zhao, Jumei
    Yang, Yue
    Dai, Qiangfang
    Zhang, Ning
    Mi, Zhikuan
    Hu, Qianqian
    Liu, Xiaolong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2025, 40 (01)
  • [34] T790M and C797S as Mechanisms of Acquired Resistance to Dacomitinib in Cell Models
    Kobayashi, Y.
    Fujino, T.
    Nishino, M.
    Ohara, S.
    Sesumi, Y.
    Chiba, M.
    Shimoji, M.
    Tomizawa, K.
    Takemoto, T.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2258 - S2259
  • [35] Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo
    Lai, Mengzhen
    Zhang, Tao
    Chen, Hao
    Song, Peiran
    Tong, Linjiang
    Chen, Jiaying
    Liu, Yingqiang
    Ning, Yi
    Feng, Fang
    Li, Yan
    Tang, Haotian
    Chen, Yi
    Fang, Yan
    Lu, Xiaoyun
    Geng, Meiyu
    Ding, Ke
    Yu, Ker
    Ding, Jian
    Xie, Hua
    JOURNAL OF CANCER, 2023, 14 (01): : 152 - 162
  • [36] Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation
    Floch, Nicolas
    Finlay, M. Raymond V.
    Bianco, Ambra
    Bickerton, Sue
    Colclough, Nicola
    Cross, Darren A.
    Cuomo, Emanuela M.
    Guerot, Carine M.
    Hargreaves, David
    Martin, Matthew J.
    McKerrecher, Darren
    O'Neill, Daniel J.
    Orme, Jonathan P.
    Rahi, Amar
    Smith, Paul D.
    Ward, Richard A.
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Orthoallosteric EGFR-TKIs: A New Paradigm in NSCLC Treatment Strategy Targeting the C797S Mutation
    Ahmad, Iqrar
    Patel, Harun M.
    DRUG DEVELOPMENT RESEARCH, 2025, 86 (01)
  • [38] EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
    Park, Sehhoon
    Ku, Bo Mi
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Lee, Se-Hoon
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1288 - 1290
  • [39] Overcoming the C797S/T790M mutation mediated Osimertinib resistance by Brigatinib combined with anti-EGFR antibody.
    Uchibori, Ken
    Fujita, Naoya
    Katayama, Ryohei
    CANCER SCIENCE, 2018, 109 : 568 - 568
  • [40] Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance
    Patil, Bhatu R.
    Patel, Harun M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283
12345